ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome everyone to ACADIA Pharmaceuticals First Quarter twenty twenty six Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Thank you. I would now like to turn the conference over to Albert Kilgarni, Senior Vice President, Investor Relations and Corporate Development. Please go ahead. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's first quarter twenty twenty six financial results. Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer, who'll provide some opening remarks followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, Debut and NUPLAZID. Also joining us today are Elizabeth Thompson, Ph. D, Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs and Mark Schneider, our Chief Financial Officer, who will review the financial highlights. Kathryn will then provide some closing remarks before we open up the call for your questions. We are using supplemental slides, which are available on our website in the Events and Presentations section. On today's call, both GAAP and non GAAP financial measures will be discussed, including non GAAP NUPLAZID net sales and non GAAP total revenues. The non GAAP financial measures that are also referred to as adjusted financial measures pertain only to NUPLAZID sales in 2025 and their impact on total revenues. All references to non GAAP are reconciled with the most directly comparable GAAP financial measures i...